Preclinical and clinical testing of a stem cell-based combination product for insulin-dependent diabetes

**Disease Area:** Type 1 diabetes

**Trial Sponsor:** ViaCyte, Inc.

**Trial Stage:** Phase 1/2

**Trial Status:** Active, not recruiting

**Targeted Enrollment:** 69

**ClinicalTrials.gov ID:** NCT02239354

**CIRM Awards Funding This Trial**

<table>
<thead>
<tr>
<th>Investigator:</th>
<th>Howard Foyt</th>
</tr>
</thead>
<tbody>
<tr>
<td>Institution:</td>
<td>ViaCyte, Inc.</td>
</tr>
</tbody>
</table>

**CIRM Grant:** SP1-06513 (Closed)

**Award Value:** $9,475,070

<table>
<thead>
<tr>
<th>Investigator:</th>
<th>Howard Foyt</th>
</tr>
</thead>
<tbody>
<tr>
<td>Institution:</td>
<td>ViaCyte, Inc.</td>
</tr>
</tbody>
</table>

**CIRM Grant:** AP1-08039

**Award Value:** $8,783,852

**Details:**
ViaCyte is developing cell therapies to replace lost pancreatic beta cells for people with type 1 diabetes (T1D). The therapies are derived from human embryonic stem cells, which are partially matured into becoming pancreatic tissues (the type destroyed in T1D). The cells are inserted into a small pouch that is transplanted under the patient’s skin. The transplanted cells will develop into fully matured beta cells that secrete the hormone insulin, which is needed to keep blood sugar levels at a healthy level. This trial is testing ViaCyte’s product candidate called VC-01. This product encapsulates the cells and protects them from the patient’s immune system.

**Design:**
Open label, multi-center, 1st in human study.

**Goal:**
Updates:
Ongoing, not recruiting.